Cell and Gene Outsourcing

  1. Bridging The Disconnect: Commercial Clarity And Communication Will Define The Future Of CGT CDMOs 7/9/2025

    As the cell and gene therapy sector emerged, large CDMOs ventured into the sector as if it were an easy extension of their biologics or small molecule business. It’s not. And that lack of understanding has created an industrywide bottleneck.

  2. The New Clinical Packaging Paradigm: Differentiation And Decentralization 7/8/2025

    The rapid evolution toward flexible, decentralized clinical supply models is placing unprecedented strain on traditional clinical packaging organizations. Can traditional models adapt fast enough to stay viable?

  3. A Complete CRISPR Workflow From The Lab To The Clinic 7/3/2025

    Explore a complete, end-to-end genome editing solution designed to support seamless transitions from lab research to clinical applications with precision and efficiency.

  4. A One-Stop Shop For All Your CRISPR Needs 7/3/2025

    Enhance your genome editing with Alt-R CRISPR-Cas enzymes, which are engineered for precision, efficiency, and flexibility. Choose from trusted Cas9 or advanced proprietary variants.

  5. CGMP Oligo Manufacturing And Services For CRISPR Therapeutics 7/3/2025

    Learn more about a company that has led oligonucleotide innovation with unmatched precision, quality, and CRISPR expertise to empower researchers worldwide to bring scientific discoveries to life.

  6. From Knowledge Management To Learning Empowerment: Talent Development 7/3/2025

    Observe how to transform biopharma learning with a human-centered, AI-enhanced ecosystem that personalizes development, fosters engagement, and aligns training with real-world impact.

  7. Empowering Biologics Development With HRMS Services 7/3/2025

    Examine ways to accelerate biologic development with high-resolution mass spectrometry services that deliver precise, reliable data from discovery through commercial release.

  8. Double-Stranded mRNA Testing By ELISA 7/3/2025

    Uncover how accurate detection of toxic double-stranded RNA impurities is critical in mRNA drug development, and expert ELISA-based solutions that support safe, effective therapeutic release.

  9. Why Fill/Finish Operations Make Or Break Viral Vector Therapies 7/3/2025

    Discover how precision fill/finish processes ensure the safety, sterility, and success of cutting-edge viral vector therapies as they move from production to patients.

  10. June 2025 — CDMO Opportunities And Threats Report 7/3/2025

    Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.